Investigational drug · Phase 3
BHV-7000
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
10
Any phase or sponsor naming "BHV-7000"
First trial start
2024
Mar 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BHV-7000", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Epilepsy
- Major Depressive Disorder
- Bipolar Disorder
Approved drugs for the same conditions: Epilepsy and seizures · Depression (major depressive disorder) · Bipolar disorder · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "BHV-7000" as an intervention, largest first.
- Long-term Safety and Tolerability of BHV-7000Enrolling by invitation
Biohaven Therapeutics Ltd.Industry
NCT06443463 · 660 participants (planned) · Start Jul 30, 2024 · Primary completion Dec 2026
Drug: BHV-7000; BHV-7000 · For: Focal Epilepsy
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 283 sites in all
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPivotal-lookingActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT06309966 · 390 participants (planned) · Start May 13, 2024 · Primary completion Oct 2026
Drug: BHV-7000; BHV-7000 and 1 more · For: Focal Epilepsy
Sites: Peoria, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 150 sites in all
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPivotal-lookingActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT06132893 · 390 participants (planned) · Start Mar 14, 2024 · Primary completion Dec 2026
Drug: BHV-7000; BHV-7000 and 3 more · For: Focal Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 104 sites in all
- Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionPivotal-lookingCompleted
Biohaven Therapeutics Ltd.Industry
NCT06419608 · 336 participants · Start May 28, 2024 · Primary completion Nov 7, 2025
Drug: BHV-7000; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 62 sites in all
- BHV-7000 Acute Treatment of Bipolar ManiaPivotal-lookingCompleted
Biohaven Therapeutics Ltd.Industry
NCT06419582 · 274 participants · Start May 28, 2024 · Primary completion Jan 15, 2025
Drug: BHV-7000; Placebo · For: Bipolar Disorder
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 32 sites in all
Biohaven Therapeutics Ltd.Industry
NCT06423781 · 233 participants · Start Aug 1, 2024 · Primary completion Mar 18, 2026
Drug: BHV-7000 · For: Major Depressive Disorder
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 66 sites in all
Biohaven Therapeutics Ltd.Industry
NCT06423794 · 94 participants · Start Jun 24, 2024 · Primary completion Apr 25, 2025
Drug: BHV-7000 · For: Bipolar Disorder
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 32 sites in all
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic SeizuresPivotal-lookingTerminated
Biohaven Therapeutics Ltd.Industry
NCT06425159 · 27 participants · Start Jun 20, 2024 · Primary completion Mar 12, 2026
Drug: BHV-7000; Placebo · For: Generalized Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 109 sites in all
- A Phase 1b Study of BHV-7000 in Participants With Inherited ErythromelalgiaActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT07262268 · 5 participants (planned) · Start Jan 15, 2026 · Primary completion Nov 2027
Drug: BHV-7000; Placebo · For: Familial Erythromelalgia
Sites: New Haven, Connecticut
Yale UniversityAcademic, hospital or other
NCT07125261 · 5 participants · Start Oct 7, 2025 · Primary completion Mar 18, 2026
Drug: BHV-700 · For: Epilepsy; Seizures
Sites: New Haven, Connecticut
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?
Pelorosso C, Balestrini S, Guerrini R · Expert Opin Emerg Drugs 2026
- Targeting Kv7 Potassium Channels for Epilepsy.
Perucca E, Taglialatela M · CNS Drugs 2025
- Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development.
Bialer M, Johannessen SI, Koepp MJ, et al. · Epilepsia 2024
Also in development for Focal Epilepsy
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- RAP-219Phase 35 trials
Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure
- Test drug CB03-154 groupPhase 32 trials
Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy
- CB03-154Phase 21 trial
Shanghai Zhimeng Biopharma, Inc. · Focal Epilepsy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.